Literature DB >> 30864186

KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male.

Xudong Shen1, Kewei Hu2, Guilian Cheng2, Liming Xu2, Zhengrong Chen3, Peng Du3, Zhixiang Zhuang1.   

Abstract

Gastric cancer is one of the top causes of cancer-related death around the world, and poor prognosis of gastric cancer is due to the lack of early detection and effective treatment especially in male. Here, we first revealed the role of histone lysine-specific demethylase 5D (KDM5D) in gastric cancer in male. KDM5D was associated with the metastasis of gastric cancer because of its critical role in the epithelial-mesenchymal transition of gastric cancer cells. Downregulation of KDM5D in gastric cancer cells significantly increase the number of migrated or invaded cells due to the increasing expressions of mesenchymal markers. Downregulation of KDM5D also promotes tumor formation of gastric cancer cell in vivo. For mechanism, downregulation of KDM5D could inhibit the demethylation in the promoter of CUL4A, which lead to the increasing expression of ZEB1 and decreasing expressions of p21 and p53. Collectively, KDM5D performed its role in metastasis of gastric cancer through demethylation in the promoter of CUL4A, and it suggested us a novel target in gastric cancer treatment in male.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CUL4A; epithelial-mesenchymal transition (EMT); gastric cancer (GC); histone lysine-specific demethylase 5D (KDM5D)

Mesh:

Substances:

Year:  2019        PMID: 30864186     DOI: 10.1002/jcb.27308

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.

Authors:  Rossella Tricarico; Emmanuelle Nicolas; Michael J Hall; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 12.531

Review 4.  Y chromosome is moving out of sex determination shadow.

Authors:  Raheleh Heydari; Zohreh Jangravi; Samaneh Maleknia; Mehrshad Seresht-Ahmadi; Zahra Bahari; Ghasem Hosseini Salekdeh; Anna Meyfour
Journal:  Cell Biosci       Date:  2022-01-04       Impact factor: 7.133

5.  KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients.

Authors:  Georg Schäfer; Nikola Bednarova; Axel Heidenreich; Helmut Klocker; Isabel Heidegger
Journal:  Transl Androl Urol       Date:  2021-10

6.  The Prognostic Value of AT-Rich Interaction Domain (ARID) Family Members in Patients with Hepatocellular Carcinoma.

Authors:  Siyi Li; Zhulin Wu; Qiuyue Li; Qiting Liang; Hengli Zhou; Yafei Shi; Rong Zhang; Huafeng Pan
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650

Review 7.  Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?

Authors:  Yasuyo Ohguchi; Hiroto Ohguchi
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.